HTA & Payer Evidence Generation: Turning RWE into Reimbursement-Ready Value (2025)
HTA & Payer Evidence Generation: Turning RWE into Reimbursement-Ready Value (2025) Building HTA and Payer Evidence Packages That Withstand Scrutiny Purpose, Decision Context, and a Harmonized Global Frame Health Technology Assessment (HTA) and payer decision-making convert clinical and economic evidence into real-world access. The audience—national HTA bodies, regional payers, hospital formulary committees, and integrated delivery…
Read More “HTA & Payer Evidence Generation: Turning RWE into Reimbursement-Ready Value (2025)” »